FAS and prostate carcinoma: Immunogenic modulation by enzalutamide was first described in murine prostate carcinomas [10], where enzalutamide up-regulated MHC-I and Fas on the surface of tumor cells, thus improving the cells' sensitivity to T-cell killing.